229 related articles for article (PubMed ID: 25949874)
1. c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma.
Kumai T; Matsuda Y; Ohkuri T; Oikawa K; Ishibashi K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
Oncoimmunology; 2015 Feb; 4(2):e976077. PubMed ID: 25949874
[No Abstract] [Full Text] [Related]
2. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
3. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.
Kobayashi H; Nagato T; Oikawa K; Sato K; Kimura S; Aoki N; Omiya R; Tateno M; Celis E
Clin Cancer Res; 2005 May; 11(10):3869-78. PubMed ID: 15897588
[TBL] [Abstract][Full Text] [Related]
4. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
[TBL] [Abstract][Full Text] [Related]
5. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
6. In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma.
Rodeberg DA; Erskine C; Celis E
J Pediatr Surg; 2007 Aug; 42(8):1396-402. PubMed ID: 17706503
[TBL] [Abstract][Full Text] [Related]
7. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
9. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
Lin N; Ku W; Song Y; Zhu J; Lu Z
Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
[TBL] [Abstract][Full Text] [Related]
10. Focal adhesion kinase as an immunotherapeutic target.
Kobayashi H; Azumi M; Kimura Y; Sato K; Aoki N; Kimura S; Honma M; Iizuka H; Tateno M; Celis E
Cancer Immunol Immunother; 2009 Jun; 58(6):931-40. PubMed ID: 18941742
[TBL] [Abstract][Full Text] [Related]
11. Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.
Hayashi R; Nagato T; Kumai T; Ohara K; Ohara M; Ohkuri T; Hirata-Nozaki Y; Harabuchi S; Kosaka A; Nagata M; Yajima Y; Yasuda S; Oikawa K; Kono M; Kishibe K; Takahara M; Katada A; Hayashi T; Celis E; Harabuchi Y; Kobayashi H
Oncoimmunology; 2020 Dec; 10(1):1856545. PubMed ID: 33457076
[TBL] [Abstract][Full Text] [Related]
12. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
14. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.
Kobayashi H; Omiya R; Sodey B; Yanai M; Oikawa K; Sato K; Kimura S; Senju S; Nishimura Y; Tateno M; Celis E
Clin Cancer Res; 2003 Nov; 9(14):5386-93. PubMed ID: 14614024
[TBL] [Abstract][Full Text] [Related]
15. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
16. In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.
Kobayashi H; Ngato T; Sato K; Aoki N; Kimura S; Tanaka Y; Aizawa H; Tateno M; Celis E
Clin Cancer Res; 2006 Jun; 12(12):3814-22. PubMed ID: 16778109
[TBL] [Abstract][Full Text] [Related]
17. Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection.
Oyoshi MK; Nagata H; Kimura N; Zhang Y; Demachi A; Hara T; Kanegane H; Matsuo Y; Yamaguchi T; Morio T; Hirano A; Shimizu N; Yamamoto K
Am J Pathol; 2003 May; 162(5):1629-38. PubMed ID: 12707047
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.
Kono M; Komatsuda H; Yamaki H; Kumai T; Hayashi R; Wakisaka R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Katada A; Hayashi T; Kobayashi H; Harabuchi Y
Oncoimmunology; 2022; 11(1):2021619. PubMed ID: 35003900
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
20. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells.
Hatakeyama N; Tamura Y; Sahara H; Suzuki N; Suzuki K; Hori T; Mizue N; Torigoe T; Tsutsumi H; Sato N
Exp Hematol; 2006 Feb; 34(2):197-207. PubMed ID: 16459188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
